Ludwig Institute for Cancer Research Limited

Mark David Noble

Dimitris Kioussis

Parmjit Singh Jat

Margot Mayer

The provision of cell lines from virtually any cell type of the animal body is greatly facilitated by transgenic non-human eukaryotic animals of the invention in which at least some cells have (i) a differentiation inhibiting sequence chromosomally incorporated under the control of a non-constitutive promotor and/or (ii) a differentiation inhibiting sequence which is itself conditionally active. Said genes are chromosomally incorporated under the control of a promotor such that expression of said sequence is normally held below an effective level, thus allowing normal cell development. However, cells taken from said animal may be prevented from completing differentiation to a non-dividing state in tissue culture by activating expression of said sequence.

Transgenic mice expressing TSSV40 large T antigen

The invention is directed to therapeutic methods for treating diseases associated with tumour necrosis factor-alpha (TNF-.alpha.) induced cell toxicity and/or complement induced cell toxicity, and improved methods for treating diseases whose therapy comprises the administration of n-acetylcysteine.

Intracellular glutathione raising agents for therapeutic treatments

The invention is directed to therapeutic methods for treating diseases associated with tumor necrosis factor-alpha (TNF-.alpha.) induced cell toxicity and/or complement induced cell toxicity, improved methods for treating diseases whose therapy comprises the administration of at least one growth factor, and improved methods for preventing cell death associated with acute tissue injury.

Growing community of inventors

London, United Kingdom

Mark David Noble